Study of Efficacy and Safety of Grazoprevir (MK-5172)/Elbasvir (MK-8742) Combination Regimen for Treatment-Naïve Participants With Chronic Hepatitis C Virus Genotypes 1, 4, and 6 (MK-5172-060)

NCT02105467 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

421

Enrollment

INDUSTRY

Sponsor class

Conditions

Chronic Hepatitis C Virus

Interventions

DRUG: Grazoprevir 100mg / Elbasvir 50 mg FDC
DRUG: Placebo to Grazoprevir / Elbasvir 50 mg FDC

Sponsor

Merck Sharp & Dohme LLC